12
views
0
recommends
+1 Recommend
2 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Therapeutic mRNAs and vaccines are being developed for a broad range of human diseases, including COVID-19. However, their optimization is hindered by mRNA instability and inefficient protein expression. Here, we describe design principles that overcome these barriers. We develop an RNA sequencing-based platform called PERSIST-seq to systematically delineate in-cell mRNA stability, ribosome load, as well as in-solution stability of a library of diverse mRNAs. We find that, surprisingly, in-cell stability is a greater driver of protein output than high ribosome load. We further introduce a method called In-line-seq, applied to thousands of diverse RNAs, that reveals sequence and structure-based rules for mitigating hydrolytic degradation. Our findings show that highly structured “superfolder” mRNAs can be designed to improve both stability and expression with further enhancement through pseudouridine nucleoside modification. Together, our study demonstrates simultaneous improvement of mRNA stability and protein expression and provides a computational-experimental platform for the enhancement of mRNA medicines.

          Abstract

          The authors develop an RNA sequencing-based platform, PERSIST-seq, to simultaneously delineate in-cell mRNA stability, ribosome load, and in-solution stability of a diverse mRNA library to derive design principles for improved mRNA therapeutics.

          Related collections

          Most cited references107

          • Record: found
          • Abstract: found
          • Article: not found

          Fast gapped-read alignment with Bowtie 2.

          As the rate of sequencing increases, greater throughput is demanded from read aligners. The full-text minute index is often used to make alignment very fast and memory-efficient, but the approach is ill-suited to finding longer, gapped alignments. Bowtie 2 combines the strengths of the full-text minute index with the flexibility and speed of hardware-accelerated dynamic programming algorithms to achieve a combination of high speed, sensitivity and accuracy.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Cutadapt removes adapter sequences from high-throughput sequencing reads

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

              Abstract Background Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and the resulting coronavirus disease 2019 (Covid-19) have afflicted tens of millions of people in a worldwide pandemic. Safe and effective vaccines are needed urgently. Methods In an ongoing multinational, placebo-controlled, observer-blinded, pivotal efficacy trial, we randomly assigned persons 16 years of age or older in a 1:1 ratio to receive two doses, 21 days apart, of either placebo or the BNT162b2 vaccine candidate (30 μg per dose). BNT162b2 is a lipid nanoparticle–formulated, nucleoside-modified RNA vaccine that encodes a prefusion stabilized, membrane-anchored SARS-CoV-2 full-length spike protein. The primary end points were efficacy of the vaccine against laboratory-confirmed Covid-19 and safety. Results A total of 43,548 participants underwent randomization, of whom 43,448 received injections: 21,720 with BNT162b2 and 21,728 with placebo. There were 8 cases of Covid-19 with onset at least 7 days after the second dose among participants assigned to receive BNT162b2 and 162 cases among those assigned to placebo; BNT162b2 was 95% effective in preventing Covid-19 (95% credible interval, 90.3 to 97.6). Similar vaccine efficacy (generally 90 to 100%) was observed across subgroups defined by age, sex, race, ethnicity, baseline body-mass index, and the presence of coexisting conditions. Among 10 cases of severe Covid-19 with onset after the first dose, 9 occurred in placebo recipients and 1 in a BNT162b2 recipient. The safety profile of BNT162b2 was characterized by short-term, mild-to-moderate pain at the injection site, fatigue, and headache. The incidence of serious adverse events was low and was similar in the vaccine and placebo groups. Conclusions A two-dose regimen of BNT162b2 conferred 95% protection against Covid-19 in persons 16 years of age or older. Safety over a median of 2 months was similar to that of other viral vaccines. (Funded by BioNTech and Pfizer; ClinicalTrials.gov number, NCT04368728.)
                Bookmark

                Author and article information

                Contributors
                mbarna@stanford.edu
                rhiju@stanford.edu
                Journal
                Nat Commun
                Nat Commun
                Nature Communications
                Nature Publishing Group UK (London )
                2041-1723
                22 March 2022
                22 March 2022
                2022
                : 13
                : 1536
                Affiliations
                [1 ]GRID grid.168010.e, ISNI 0000000419368956, Department of Genetics, , Stanford University, ; Stanford, CA 94305 USA
                [2 ]GRID grid.168010.e, ISNI 0000000419368956, Department of Biochemistry, , Stanford University, ; Stanford, CA 94305 USA
                [3 ]GRID grid.168010.e, ISNI 0000000419368956, Department of Chemistry, , Stanford University, ; Stanford, CA 94305 USA
                [4 ]GRID grid.168010.e, ISNI 0000000419368956, Program in Biophysics, , Stanford University, ; Stanford, CA 94305 USA
                [5 ]GRID grid.168010.e, ISNI 0000000419368956, Department of Bioengineering, , Stanford University, ; Stanford, CA 94305 USA
                [6 ]GRID grid.168010.e, ISNI 0000000419368956, Eterna Massive Open Laboratory, , Stanford University, ; Stanford, CA 94305 USA
                [7 ]GRID grid.273335.3, ISNI 0000 0004 1936 9887, Department of Computer Science and Engineering, , State University of New York at Buffalo, Buffalo, ; New York, 14260 USA
                [8 ]GRID grid.451133.1, ISNI 0000 0004 0458 4453, NVIDIA Corporation, ; 2788 San Tomas Expy, Santa Clara, CA 95051 USA
                [9 ]Pfizer Vaccine Research and Development, Pearl River, NY USA
                [10 ]GRID grid.418019.5, ISNI 0000 0004 0393 4335, Present Address: GlaxoSmithKline, ; 1000 Winter St., Waltham, MA 02453 USA
                Author information
                http://orcid.org/0000-0002-8012-8076
                http://orcid.org/0000-0003-3332-5285
                http://orcid.org/0000-0001-8871-9682
                http://orcid.org/0000-0002-7818-2161
                http://orcid.org/0000-0003-4031-0102
                http://orcid.org/0000-0002-2646-8133
                http://orcid.org/0000-0003-0671-6360
                http://orcid.org/0000-0003-0072-3463
                http://orcid.org/0000-0002-6843-4396
                http://orcid.org/0000-0001-7497-0972
                Article
                28776
                10.1038/s41467-022-28776-w
                8940940
                35318324
                c3cd15a0-9c17-44e2-94a2-78faf9a6d4f1
                © The Author(s) 2022

                Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

                History
                : 8 April 2021
                : 7 February 2022
                Categories
                Article
                Custom metadata
                © The Author(s) 2022

                Uncategorized
                rna,rna decay,rna folding,translation,molecular medicine
                Uncategorized
                rna, rna decay, rna folding, translation, molecular medicine

                Comments

                Comment on this article